Koelis develops the Koelis Trinity, a system offering stand-alone ultrasound imaging and MRI fusion guidance for prostate biopsy and minimally invasive prostate cancer treatments. The Trinity features proprietary 3D ultrasound imaging and prostate motion tracking software (OBT Fusion®) to improve biopsy accuracy and enable focal treatment alternatives to whole-organ therapies. The company is running clinical-stage focal treatment programs, including the prospective multi-center Violette registry using microwave technology and a multi-center clinical evaluation of its focal cryoablation image guidance software. Koelis announced a completed follow-on €10 million growth equity financing that will support continued commercial expansion and its clinical and technology initiatives. Management states the financing will accelerate the company’s role in transforming prostate cancer diagnosis and treatment. The company presented the news in a release datelined Grenoble, France and Princeton, N.J. Koelis develops image-guided systems for diagnosis and treatment of prostate cancer, with its flagship Koelis Trinity™ platform. Trinity offers market-leading features including fusion imaging, organ tracking, robotic assistance, and focal therapy. The company’s products have received regulatory approvals and are commercialized in the United States, Europe, and most Asian markets. Koelis is based in Grenoble, France and Boston, Massachusetts, and maintains an office in Hong Kong. InnovaHealth Partners and Medevice Partners have invested in the company, with InnovaHealth acquiring a majority stake to support global growth. Management and investors expect to leverage InnovaHealth’s medtech expertise, clinician network, and capital to expand Koelis’s commercial footprint and create value.

Total raised

$11M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2022